These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31345736)

  • 41. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
    Gentilella R; Pechtner V; Corcos A; Consoli A
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
    Sun F; Wu S; Guo S; Yu K; Yang Z; Li L; Zhang Y; Quan X; Ji L; Zhan S
    Diabetes Res Clin Pract; 2015 Oct; 110(1):26-37. PubMed ID: 26358202
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
    Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
    Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dispensing of Glucagon-Like Peptide-1 Receptor Agonists to Adolescents and Young Adults, 2020-2023.
    Lee JM; Sharifi M; Oshman L; Griauzde DH; Chua KP
    JAMA; 2024 Jun; 331(23):2041-2043. PubMed ID: 38776113
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders.
    Wroge J; Williams NT
    Ann Pharmacother; 2016 Dec; 50(12):1041-1050. PubMed ID: 27531946
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.
    Burcelin R; Gourdy P
    Obes Rev; 2017 Jan; 18(1):86-98. PubMed ID: 27636208
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Liraglutide Therapy in a Prediabetic State: Rethinking the Evidence.
    Papaetis GS
    Curr Diabetes Rev; 2020; 16(7):699-715. PubMed ID: 31886752
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor-Expressing Glutamatergic Neurons.
    Adams JM; Pei H; Sandoval DA; Seeley RJ; Chang RB; Liberles SD; Olson DP
    Diabetes; 2018 Aug; 67(8):1538-1548. PubMed ID: 29776968
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.
    Lim S; Kim KM; Nauck MA
    Trends Endocrinol Metab; 2018 Apr; 29(4):238-248. PubMed ID: 29463450
    [TBL] [Abstract][Full Text] [Related]  

  • 50. GLP-1 receptor agonist confer target organ protection in type 2 diabetes.
    Bonnet F
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S1-2S2. PubMed ID: 28431665
    [No Abstract]   [Full Text] [Related]  

  • 51. Albiglutide for the management of type 2 diabetes.
    Rendell MS
    Expert Rev Endocrinol Metab; 2018 Jan; 13(1):1-8. PubMed ID: 30063441
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Why is a combination of basal insulin with a GLP-1 receptor agonist useful in many patients with type 2 diabetes?].
    Nauck M; Wilhelm B
    MMW Fortschr Med; 2017 Jun; 159(Suppl 5):7-15. PubMed ID: 28643293
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials.
    Al Yami MS; Alfayez OM; Alsheikh R
    Heart Lung Circ; 2018 Nov; 27(11):1301-1309. PubMed ID: 29887418
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
    Simó R; Hernández C
    Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1005-1007. PubMed ID: 27659856
    [No Abstract]   [Full Text] [Related]  

  • 55. Cardiovascular safety of liraglutide for the treatment of type 2 diabetes.
    Chudleigh RA; Bain S
    Expert Opin Drug Saf; 2017 May; 16(5):627-635. PubMed ID: 28387138
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Liraglutide: A Glucagon-Like Peptide-1 Agonist for Chronic Weight Management.
    Manigault KR; Thurston MM
    Consult Pharm; 2016 Dec; 31(12):685-697. PubMed ID: 28074747
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study.
    Otto T; Myland M; Jung H; Lebrec J; Richter H; Norrbacka K
    Curr Med Res Opin; 2019 May; 35(5):893-901. PubMed ID: 30328731
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population.
    Wittbrodt ET; Eudicone JM; Bell KF; Enhoffer DM; Latham K; Green JB
    Am J Manag Care; 2018 Apr; 24(8 Suppl):S146-S155. PubMed ID: 29693361
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment evaluation of liraglutide in type 2 diabetes.
    Kela R; Davies MJ
    Expert Opin Biol Ther; 2012 Nov; 12(11):1551-6. PubMed ID: 22897447
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis.
    Peterson SC; Barry AR
    Curr Diabetes Rev; 2018; 14(3):273-279. PubMed ID: 28413990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.